How This Small Washington Biotech Stands To Outperform Rivals Amgen, Eli Lilly And Teva In Migraine Drugs

Published: Jun 09, 2017

Wall Street is undervaluing Alder Biopharmaceuticals (ALDR) which stands to outperform larger rivals Amgen, Eli Lilly and Teva Pharmaceutical in migraine drugs, an analyst said Thursday ahead of a key conference on headache treatments.

Needham analyst Danielle Brill maintained her buy rating and 36 price target on Alder stock. On the stock market today, Alder stock climbed 1.2% to 16.55. Alder is set to present data this weekend from a Phase 2 clinical trial of a treatment for frequent episodic migraines. Phase 3 data from the trial dubbed Promise-1 is expected by the end of the month.

Back to news